Premium
Cytologic and cystoscopic predictors of recurrence and progression in patients with low‐grade urothelial carcinoma
Author(s) -
Jackson Julie,
Barkan Güliz A.,
Kapur Umesh,
Wojcik Eva M.
Publication year - 2013
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.29
H-Index - 57
eISSN - 1934-6638
pISSN - 1934-662X
DOI - 10.1002/cncy.21272
Subject(s) - medicine , cystoscopy , urine cytology , cytology , biopsy , carcinoma , urology , urothelial carcinoma , bladder cancer , cancer , urinary system , pathology
BACKGROUND Patients with low‐grade urothelial carcinoma (LGUC) are at risk of recurrence and must undergo lifelong surveillance. To date, cytology and cystoscopy are the gold standard for the detection of de novo and recurrent LGUC. The objective of the current study was is to further characterize the role of cytology and cystoscopy in determining the risk of recurrence and progression in these patients. METHODS The authors retrospectively identified patients with LGUC who had urine cytology within 2 months of biopsy, and data were abstracted from their electronic charts. Electronic medical records were reviewed for cystoscopic findings and histologic and cytologic follow‐up data over a 5‐year period. Statistical analysis was performed with chi‐square tests. RESULTS In total, 76 patients were identified who had histologic follow‐up material available, and 49% of those patients demonstrated progression or recurrence of urothelial carcinoma. The initial presence of multiple lesions on cystoscopy was associated with any recurrence or progression (67.7% vs 31%; P = .002), tumor size >2 cm was associated with initial positive or suspicious urine cytology (23.8% vs 3.7%; P = .076), and positive or suspicious initial cytology was associated with high‐grade recurrence (58.3% vs 19.4%; P = .009). CONCLUSIONS Cystoscopic findings, such as the presence of multiple lesions, together with concurrent positive or suspicious urine cytology, were associated with recurrence or progression of LGUC. These findings may help to identify high‐risk patients. Cancer (Cancer Cytopathol) 2012;121:398–402. © 2012 American Cancer Society.